Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma

Man Hsin Hung  1   2   3 , Xin Wei Wang  1   4
Yujin Hoshida  1
, editors.
In: Hepatocellular Carcinoma: Translational Precision Medicine Approaches [Internet]. Cham (CH): Humana Press; 2019. Chapter 14.
.
Affiliations
Free Books & Documents
Review

Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma

Man Hsin Hung et al.
Free Books & Documents

Excerpt

Hepatocellular carcinoma (HCC) is a fatal disease without effective treatment. In recent decades, numbers of molecular profiling studies have improved our understanding of critical oncogenic events driving hepatocarcinogenesis and identified potential molecular targets for drug development in HCC. However, these studies have also revealed the heterogeneous nature of this disease and underscore the impact of intertumoral and/or intratumoral heterogeneity of HCC on a successful treatment. In this chapter, we will summarize common HCC-associated molecular alterations, review data related to molecular heterogeneity, understand what drives the evolution of HCC heterogeneity and how this knowledge would lead us to generate new research directions, and improve the outcome of HCC patients.

PubMed Disclaimer

References

    1. Wong MCS, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FDH, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 2017;7:45846. https://doi.org/10.1038/srep45846. https://www.nature.com/articles/srep45846#supplementary-information. - DOI - PMC - PubMed
    1. ClinicalTrials.gov. Interventional studies | hepatocellular carcinoma. Bethesda (MD): National Library of Medicine (US); 2018. https://www.clinicaltrials.gov/ct2/results?cond=Hepatocellular+Carcinoma.... Accessed June 14 2018.
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. - PubMed
    1. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9. - DOI - PubMed
    1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1. - DOI - PubMed

LinkOut - more resources